Related Experiment Video
Updated: May 27, 2026
08:21
Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
Cardiovascular pharmacogenetics
Renier Myburgh1, Warren E Hochfeld, Tyren M Dodgen
1Department of Immunology, Faculty of Health Sciences, University of Pretoria, South Africa.
Pharmacology & Therapeutics
|November 30, 2011
Summary
Human genetic variations influence drug response and adverse reactions in cardiovascular disease treatment. Understanding these genetic factors can optimize drug efficacy and minimize toxicity through personalized medicine approaches.
Area of Science:
- Pharmacogenetics
- Cardiovascular Medicine
- Genetics
Background:
- Human genetic variations, including single nucleotide polymorphisms and structural variations, contribute to diverse clinical responses to pharmacotherapeutic drugs.
- These variations impact the likelihood of adverse drug reactions and the achievement of therapeutic success.
Purpose of the Study:
- To review key studies in cardiovascular pharmacogenetics.
- To highlight genetic variations influencing drug treatment outcomes in cardiovascular disease.
- To describe genetic associations with drug efficacy and toxicity.
Main Methods:
- Review of key studies in cardiovascular pharmacogenetics.
- Analysis of genetic associations with drug efficacy and toxicity.
- Examination of genetic variability in pharmacokinetics and pharmacodynamics.
Main Results:
- Genetic variations play a role in drug efficacy and toxicity in cardiovascular medicine.
- Variability in drug metabolizing enzymes (pharmacokinetics) and drug targets (pharmacodynamics) are key factors.
- Identified genetic associations provide functional insights into drug response.
Conclusions:
- Genetic variations significantly affect cardiovascular drug treatment outcomes.
- Understanding these genetic underpinnings can lead to the development of predictive genetic tests.
- The goal is to minimize drug toxicity and optimize therapeutic efficacy in cardiovascular medicine.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...